• Fernando Armestar, Sara Vitoria Rubio, Isabel Ojanguren Sabán, Jaume Coll-Cantí, and Hipólito Perez Molto.
• Servicio de Medicina Intensiva, Hospital Universitario Germans Trias i Pujol, Barcelona, España; Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, España. Electronic address: farmestar.germanstrias@gencat.cat.
• Med Clin (Barc). 2024 Oct 18; 163 (7): 323326323-326.

BackgroundAcquired critical illness weakness (AWCIP) is the most frequent neuromuscular disease in intensive care medicine departments. Its importance is given by the prolongation of hospital stay and the delayed recovery it causes to patients after hospitalization. The main objective of this study was to investigate the association between neuromuscular blocking agents and the development of acquired weakness in critically ill patients.Material And MethodsWe conducted a prospective study of 103 critically ill patients who were periodically monitored with electromyography.ResultsThe development of AWCIP was observed in 63 patients. The group of patients who developed AWCIP had a significantly higher utilization of neuromuscular blocking agents than the group who did not develop AWCIP [79.4% vs 50%, OR:3.85 (1.63-9.39), p <0.02]; likewise, this group of patients had a longer ICU stay [32 days vs 14 days, OR: 1.11 (1.06-1.17), p <0. 001] and a longer mechanical ventilation time [24 days vs 9 days, OR:1.2 (1.11-1.32), p <0.001].ConclusionNeuromuscular blocking agents are a factor associated with the occurrence of AWCIP.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

26 keywords...

hide…